Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: Participation ofimidazoline and norepinephrine receptors

Neuropsychopharmacology

Volumn 28, Issue 6, 2003, Pages 1140-1149

  Georges, François ^a,b   Aston Jones, Gary ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CNRS   (France)

Author keywords

Addiction; Dopamine neuronsventral tegmentalarea; Extracellular recording; Imidazoline receptors; Rilmenidine

Indexed keywords

ADRENERGIC RECEPTOR; CLONIDINE; DOPAMINE; DRUG RECEPTOR; IMIDAZOLINE RECEPTORS;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; LIMBIC SYSTEM; METABOLISM; MORPHINE ADDICTION; NERVE CELL; PHYSIOLOGY; RAT; REACTION TIME; SPRAGUE DAWLEY RAT; WITHDRAWAL SYNDROME;

ANIMALS; CLONIDINE; DOPAMINE; LIMBIC SYSTEM; MORPHINE DEPENDENCE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, ADRENERGIC; RECEPTORS, DRUG; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0041342079     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300161     Document Type: Article

References (68)

1. Acquas E, Carboni E, Di Chiara G (1991). Profound depression of mesolimbic dopamine release after morphine withdrawal independent rats.Eur J Pharmacol193: 133-134.
2. Aghajanian GK (1978). Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine.Nature276: 186-188.
3. Aghajanian GK, Cedarbaum JM, Wang RY (1977). Evidence for norepinephrine-mediated collateral inhibition of locus coeruleusneurons.Brain Res136: 570-577.
4. Akaoka H, Aston-Jones G (1991). Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantiallymediated by augmented excitatory amino acid input.J Neurosci11: 3830-3833.
5. Andorn AC, Carlson MA, Gilkeson RC (1988). Specific [3H]UK 14, 304 binding in human cortex occurs at multiple high affinitystates with alpha 2-adrenergic selectivity and differing affinitiesfor GTP.Life Sci43: 1805-1812.
6. Aston-Jones G, Delfs JM, Druhan J, Zhu Y (1999). The bed nucleus of the stria terminalis. A target site for noradrenergic actions inopiate withdrawal.Ann NY Acad Sci877: 486-498.
7. Bousquet P (2001). I1 receptors, cardiovascular function, and metabolism.Am J Hypertens14: 317S-321S.
8. Bousquet P, Bruban V, Schann S, Feldman J (2000). Imidazoline receptors: a challenge.Pharm Acta Helv74: 205-209.
9. Bousquet P, Feldman J (1999). Drugs acting on imidazoline receptors: a review of their pharmacology, their use in bloodpressure control and their potential interest in cardioprotection.Drugs58: 799-812.
10. Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P (1989). The imidazoline preferring receptor: bindingstudies in bovine, rat and human brainstem.Eur J Pharmacol162: 1-9.
11. Bricca G, Zhang J, Greney H, Dontenwill M, Stutzmann J, Belcourt Aet al(1993). Relevance of the use of [3H]-clonidine to identifyimidazoline receptors in the rabbit brainstem.Br J Pharmacol110: 1537-1543.
12. Bruban V, Estato V, Schann S, Ehrhardt JD, Monassier L, Renard Pet al(2002). Evidence for synergy between alpha(2)-adrenergicand nonadrenergic mechanisms in central blood pressureregulation. Circulation105: 1116-1121.
13. Buccafusco JJ, Lapp CA, Westbrooks KL, Ernsberger P. (1995). Role of medullary I1-imidazoline and alpha 2-adrenergicreceptors in the antihypertensive responses evoked by centraladministration of clonidine analogs in conscious spontaneouslyhypertensive rats.J Pharmacol Exp Ther273: 1162-1171.
14. Buccafusco JJ, Marshall DC, Turner RM (1984). A comparison of the inhibitory effects of clonidine and guanfacine on thebehavioral and autonomic components of morphine withdrawalin rats.Life Sci35: 1401-1408.
15. Caille S, Espejo EF, Reneric JP, Cador M, Koob GF, Stinus L (1999). Total neurochemical lesion of noradrenergic neurons of thelocus ceruleus does not alter either naloxone-precipitated orspontaneous opiate withdrawal nor does it influence ability ofclonidine to reverse opiate withdrawal.J Pharmacol Exp Ther290: 881-892.
16. Cedarbaum JM, Aghajanian GK (1976). Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation bythe alpha-antagonist piperoxane.Brain Res112: 413-419.
17. Coupar IM (1992). Effect of alpha 2-adrenoceptor agonists on the expression of morphine-withdrawal in rats.Naunyn Schmiedebergs Arch Pharmacol345: 553-557.
18. De Vos H, Bricca G, De Keyser J, De Backer JP, Bousquet P, Vauquelin G (1994). Imidazoline receptors, non-adrenergicidazoxan binding sites and alpha 2-adrenoceptors in the humancentral nervous system.Neuroscience59: 589-598.
19. De Vries TJ, Shippenberg TS (2002). Neural systems underlying opiate addiction.J Neurosci22: 3321-3325.
20. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G (2000). Noradrenaline in the ventral forebrain is critical for opiate withdrawal-inducedaversion.Nature403: 430-434.
21. Diana M, Pistis M, Muntoni A, Gessa G (1995). Profound decrease of mesolimbic dopaminergic neuronal activity in morphinewithdrawn rats.J Pharmacol Exp Ther272: 781-785.
22. Drouin C, Blanc G, Villegier AS, Glowinski J, Tassin JP (2002a). Critical role of alpha1-adrenergic receptors in acute andsensitized locomotor effects of D-amphetamine, cocaine, andGBR 12783: influence of preexposure conditions and pharmacological characteristics.Synapse43: 51-61.
23. Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia Set al(2002b). Alpha1b-adrenergic receptors control locomotorand rewarding effects of psychostimulants and opiates.JNeurosci22: 2873-2884.
24. Ennis M, Aston-Jones G (1988). Activation of locus coeruleus from nucleus paragigantocellularis: a new excitatory amino acidpathway in brain.J Neurosci8: 3644.
25. Ernsberger P, Damon TH, Graff LM, Schafer SG, Christen MO (1993). Moxonidine, a centrally acting antihypertensive agent, isa selective ligand for I1-imidazoline sites.J Pharmacol Exp Ther264: 172-182.
26. Ernsberger P, Friedman JE, Koletsky RJ (1997). The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.J Hypertens15(Suppl): S9-S23.
27. Ernsberger P, Meeley MP, Mann JJ, Reis DJ (1987). Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in theventrolateral medulla.Eur J Pharmacol134: 1-13.
28. Fuentealba JA, Forray MI, Gysling K (2000). Chronic morphine treatment and withdrawal increase extracellular levels ofnorepinephrine in the rat bed nucleus of the stria terminalis.JNeurochem75: 741-748.
29. Garcia-Sevilla JA, Escriba PV, Guimon J (1999). Imidazoline receptors and human brain disorders.Ann NY Acad Sci881: 392-409.
30. Georges F, Aston-Jones G (2002). Activation of ventral tegmental area cells by the bed nucleus of the stria terminalis: a novelexcitatory amino acid input to midbrain dopamine neurons.JNeurosci22: 5173-5187.
31. Gobbi G, Muntoni AL, Gessa GL, Diana M (2001). Clonidine fails to modify dopaminergic neuronal activity during morphine withdrawal.Psychopharmacology (Berl)158: 1-6.
32. Gold MS, Pottash AL, Extein I, Kleber HD (1980). Clonidine and opiate withdrawal [letter].Lancet2: 1078-1079.
33. Gold LH, Stinus L, Inturrisi CE, Koob GF (1994). Prolonged tolerance, dependence and abstinence following subcutaneous morphinepellet implantation in the rat.Eur J Pharmacol253: 45-51.
34. Gossop M (1988). Clonidine and the treatment of the opiate withdrawal syndrome.Drug Alcohol Depend21: 253-259.
35. Gowing LR, Farrell M, Ali RL, White JM (2002). Alpha2-adrenergic agonists in opioid withdrawal.Addiction97: 49-58.
36. Grace AA, Bunney BS (1983). Intracellular and extracellular electrophysiology of nigral dopaminergic neurons—1. Identification and characterization.Neuroscience10: 301-315.
37. Grace AA, Bunney BS (1984). The control of firing pattern in nigral dopamine neurons: single spike firing.J Neurosci4: 2866-2876.
38. Grenhoff J, Svensson TH (1993). Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area.Eur JPharmacol233: 79-84.
39. Guyenet PG, Aghajanian GK (1978). Antidromic identification of dopaminergic and other output neurons of the rat substantianigra.Brain Res150: 69-84.
40. Harris GC, Aston-Jones G (1994). Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawalsyndrome [see comments].Nature371: 155-157.
41. Herve D, Blanc G, Glowinski J, Tassin JP (1982). Reduction of dopamine utilization in the prefrontal cortex but not in thenucleus accumbens after selective destruction of noradrenergicfibers innervating the ventral tegmental area in the rat.Brain Res237: 510-516.
42. Hudson AL, Robinson ES, Lalies MD, Tyacke RJ, Jackson HC, Nutt DJ (1999).In vitroandin vivoapproaches to the characterizationof the alpha2-adrenoceptor.J Auton Pharmacol19: 311-320.
43. Jansson CC, Pohjanoksa K, Lang J, Wurster S, Savola JM, Scheinin M (1999). Alpha2-adrenoceptor agonists stimulate high-affinityGTPase activity in a receptor subtype-selective manner.Eur JPharmacol374: 137-146.
44. Kawahara H, Kawahara Y, Westerink BH (2001). The noradrenaline-dopamine interaction in the rat medial prefrontal cortex studied by multi-probe microdialysis.Eur J Pharmacol418: 177-186.
45. King PR, Gundlach AL, Louis WJ (1995). Quantitative autoradiographic localization in rat brain of alpha 2-adrenergic and nonadrenergic I-receptor binding sites labelled by [3H]rilmenidine.Brain Res675: 264-278.
46. Kosten TA (1994). Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal.Eur JPharmacol254: 59-63.
47. Laviolette SR, Nader K, van der Kooy D (2002). Motivational state determines the functional role of the mesolimbic dopaminesystem in the mediation of opiate reward processes.Behav BrainRes129: 17-29.
48. Maldonado R (1997). Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence.Neurosci Biobehav Rev21: 91-104.
49. Mallard NJ, Hudson AL, Nutt DJ (1992). Characterization and autoradiographical localization of non-adrenoceptor idazoxanbinding sites in the rat brain.Br J Pharmacol106: 1019-1027.
50. Mattick RP, Hall W (1996). Are detoxification programmes effective?Lancet347: 97-100.
51. Meana JJ, Herrera-Marschitz M, Goiny M, Silveira R (1997). Modulation of catecholamine release by alpha 2-adrenoceptorsand I1-imidazoline receptors in rat brain.Brain Res744: 216-226.
52. Meltzer LT, Christoffersen CL, Serpa KA (1997). Modulation of dopamine neuronal activity by glutamate receptor subtypes.Neurosci Biobehav Rev21: 511-518.
53. Michel MC, Brodde OE, Schnepel B, Behrendt J, Tschada R, Motulsky HJet al(1989). [3H]idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergicsite.Mol Pharmacol35: 324-330.
54. Nowycky MC, Walters JR, Roth RH (1978). Dopaminergic neurons: effect of acute and chronic morphine administration on single cellactivity and transmitter metabolism.J Neural Trans42: 99-116.
55. Olmos G, Miralles A, Barturen F, Garcia-Sevilla JA (1992). Characterization of brain imidazoline receptors in normotensiveand hypertensive rats: differential regulation by chronic imidazoline drug treatment.J Pharmacol Exp Ther260: 1000-1007.
56. Pothos E, Rada P, Mark GP, Hoebel BG (1991). Dopamine microdialysis in the nucleus accumbens during acute andchronic morphine, naloxone-precipitated withdrawal and clonidine treatment.Brain Res566: 348-350.
57. Rabinowitz J, Cohen H, Tarrasch R, Kotler M (1997). Compliance to naltrexone treatment after ultra-rapid opiate detoxification:an open label naturalistic study.Drug Alcohol Depend47: 77-86.
58. Rossetti ZL, Longu G, Mercuro G, Gessa GL (1993). Extraneuronal noradrenaline in the prefrontal cortex of morphine-dependent rats:tolerance and withdrawal mechanisms.Brain Res609: 316-320.
59. Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ (1998). Immunocytochemical localization of an imidazoline receptorprotein in the central nervous system.Brain Res780: 270-293.
60. Santi AN, Parker LA (2001). The dopamine antagonist, alpha-flupenthixol, interferes with naloxone-induced place aversion learning, but not with acute opiate dependence in rats.Pharmacol Biochem Behav70: 193-197.
61. Schann S, Bruban V, Pompermayer K, Feldman J, Pfeiffer B, Renard Pet al(2001). Synthesis and biological evaluation ofpyrrolinic isosteres of rilmenidine. Discovery ofcis-/trans-dicyclopropylmethyl-(4, 5-dimethyl-4, 5-dihydro-3H-pyrrol-2-yl)-a mine (LNP 509), an I1 imidazoline receptor selective ligandwith hypotensive activity.J Med Chem44: 1588-1593.
62. Schulteis G, Stinus L, Risbrough VB, Koob GF (1998). Clonidine blocks acquisition but not expression of conditioned opiatewithdrawal in rats.Neuropsychopharmacology19: 406-416.
63. Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS (2000). Dual effects ofD-amphetamine on dopamine neurons mediated bydopamine and nondopamine receptors.J Neurosci20: 3504-3511.
64. Suaud-Chagny MF, Chergui K, Chouvet G, Gonon F (1992). Relationship between dopamine release in the rat nucleusaccumbens and the discharge activity of dopaminergic neuronsduring localin vivoapplication of amino acids in the ventraltegmental area.Neuroscience49: 63-72.
65. Tepper JM, Young SJ, Groves PM (1984). Autoreceptor-mediated changes in dopaminergic terminal excitability: effects ofincreases in impulse flow.Brain Res309: 309-316.
66. Tierney C, Nadaud D, Koenig-Berard E, Stinus L (1988). Effects of two alpha 2 agonists, rilmenidine and clonidine, on themorphine withdrawal syndrome and their potential addictiveproperties in rats.Am J Cardiol61: 35D-38D.
67. Urban R, Szabo B, Starke K (1995). Involvement of alpha 2-adrenoceptors in the cardiovascular effects of moxonidine.Eur J Pharmacol282: 19-28.
68. Wallace DR, Muskardin DT, Zahniser NR (1994). Pharmacological characterization of [3H]idazoxan, [3H]RX821002 and p-[125I]iodoclonidine binding to alpha 2-adrenoceptors in ratcerebral cortical membranes.Eur J Pharmacol258: 67-76.